Skip to main content Skip to section navigation Skip to footer
180 Life Sciences Corp.
  • Home
  • Home
  • About Us
  • Programs
    • Anti-TNF
    • Synthetic CBD Analogs (SCAs)
    • a7nAChR Program
  • Pipeline
  • Leadership
  • Investors
  • Contact Us
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 30, 2021 8:30am EDT

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

Sep 20, 2021 8:00am EDT

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications

Aug 30, 2021 8:30am EDT

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

Aug 24, 2021 8:30am EDT

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement

Aug 19, 2021 9:00am EDT

180 Life Sciences Corp. Announces $15.0 Million Private Placement

Aug 02, 2021 8:00am EDT

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021

Jul 29, 2021 8:00am EDT

180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

Jul 28, 2021 8:15am EDT

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Jul 20, 2021 8:00am EDT

180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jul 12, 2021 9:51am EDT

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Copyright 2012 - 2025 | 180 Life Sciences Corp. | All Rights Reserved.
  • Visit us on Twitter Twitter
  • Visit us on Linkedin Linkedin